Background: Photodynamic therapy (PDT) involves the activation of a photosensitiser by visible light to produce activated oxygen species within target cells, resulting in their destruction. Evidence-based guidelines support the efficacy of PDT using topical 5-aminolaevulinic acid (ALA-PDT) in actinic keratoses, Bowen's disease and basal cell carcinoma (BCC). Efficacy for nodular BCC appears inferior to that for superficial BCC unless prior debulking or repeat treatments are performed.
INTRODUCTION
Photodynamic therapy (PDT) is a sophisticated, selective method of ablating tissue. It involves the activation of a photosensitising drug by visible light to produce activated oxygen species within target cells, resulting in their destruction. 1 Topically active agents are preferable for PDT in dermatology and the most experience to date has been with the photosensitising agent ALA (5-aminolaevulinic acid, ALA) prepared as a cream 2 . This is a precursor in the haem biosynthesis pathway, which occurs in all nucleated cells. Administration of ALA results in the formation of the endogenous photosensitiser, protoporphyrin IX (PpIX). This molecule normally binds with iron to form haem 1 . PDT then involves the in situ activation of the pre-administered photosensitiser (in this case ALA-derived PpIX) by a specific wavelength of light (635 nm) in the presence of molecular oxygen resulting in necrosis/apoptosis of the tumour cells 1 .
ALA-PDT for the treatment of the most common form of skin cancer, basal cell carcinoma (BCC) has received considerable attention in recent years. There is a substantial subset of BCC which are currently difficult to treat by conventional therapies because of size, site or multiple lesion presentation. Topical PDT may be advantageous in these situations and is associated with excellent cosmesis also making it an attractive option for cosmetically sensitive sites 3 . Results show that PDT produces good results as long as the disease remains superficial 4 . Efficacy for nodular BCC however appears inferior to standard treatment unless prior debulking or repeat treatments are performed 5, 6 Clearance rates for ALA-PDT in superficial and nodular BCC are highly variable, with average rates of 87% and 53% respectively for 12 studies treating 826 superficial and 208 nodular BCC 7 . It is important therefore to try and improve treatment in these thicker lesions, and various adaptations to the standard treatment have been considered.
One proposed method for increasing efficacy is to increase the levels of the photosensitiser, PpIX within cells (which are already being treated with maximal ALA doses), through the addition of an iron chelating agent. In vitro studies have
shown that by using an iron chelator, the conversion of PpIX to haem is inhibited by removing Fe 2+ from the cellular system, resulting in an increased temporary accumulation of PpIX, which can then be utilised for PDT (Figure1). In addition to this, the resultant low intracellular iron concentration also inhibits translation of ALA synthase mRNA, which would normally be a major point of regulation for this pathway 8 .
Iron chelators such as desferrioxamine (DFO) and ethylenediamine tetraacetic acid (EDTA) have been investigated as potential enhancers of ALA-PDT. Combinations of EDTA (a nonspecific chelator and antioxidant) and dimethylsulphoxide (DMSO, principally a penetration enhancer) have been used during ALA-PDT to try and increase treatment effect 9, 10 . The combination of EDTA and DMSO with ALA, in comparison with ALA alone, indicates improved penetration of ALA and PpIX accumulation in BCC 10 but there was no measurable increase in PpIX levels when EDTA was the only additive employed 10, 11 . DFO, on the other hand, is both specific for iron and can penetrate into the cellular cytosol 12 resulting in an increased enhancement of ALA-PDT 12 Relatively little research has been conducted previously on the effects of the novel iron chelator, 1,2-diethyl-3-hydroxypyridin-4-one hydrochloride (CP94) (Figure 2) on ALA induced PDT. The hydroxypyridinones are a relatively new series of ironchelating agents. They are of lower molecular weight and greater lipophilicity than previously studied iron chelators, eg. DFO, facilitating absorption directly into the skin and they enter the intracellular iron pools rapidly, being neutrally charged 13 .
They were originally developed to supersede DFO for the treatment of thalassaemia and other disorders of iron overload. They have greater affinity for iron than DFO being bidentate (rather than hexadentate), binding to iron in the ratio of 3:1, compared to 1:1 with DFO 14 .
In vivo studies have shown that CP94 enhances porphyrin fluorescence and photosensitivity in all cell lines studied 15 . Recent studies by Pye and Curnow have shown that CP94 is superior to DFO at increasing PpIX fluorescence in cultured human cells 16 .
Animal studies have shown that the outcome of ALA-PDT can be significantly enhanced by the addition of CP94. Preliminary studies in a rat colonic tumour model have shown that CP94 can double the depth of effect produced by ALA alone and increase the volume of necrosis 7-fold 17 . A topical pilot study in normal rat skin showed that ALA-PDT + CP94 tripled the effect of ALA alone 18 . These findings however have not been applied clinically previously and the investigation reported here is the first to do so. Previous research has shown that CP94 can be administered orally to patients with iron-overload without significant toxicity to produce rapid and effective iron mobilization suggesting its safety in topical use as employed here 19 . It is 6 unlikely that CP94 will be absorbed to any extent into the plasma when applied topically to the skin and any systemic circulation will be rapidly cleared by first pass metabolism (glucoronidation) in the liver.
The aim of this study, therefore, was to assess the safety and determine an indication of efficacy, of a simple pharmacological modification to single visit ALA-PDT for the treatment of nodular BCC (without prior debulking), by incorporating the novel iron chelating agent, CP94, into the ALA cream, to temporarily further enhance the accumulation of the active photosensitiser. By slowly increasing the concentration of CP94 the safety profile could be monitored in a controlled manner.
MATERIALS and METHODS
A parallel, open, dose-escalating, pilot study was conducted by two centres: Royal Each patient had a solitary, previously untreated, nodular BCC. Twenty lesions were located on the face or neck, seven on the limbs and nine on the trunk and back.
Each lesion had a minimum diameter of 5 mm and a maximum diameter of 20 mm.
Patients under the age of 18 and pregnant women were excluded from the study.
Patients within the child-bearing years were only included if they were able to use adequate contraceptive measures. Patients taking photoactive drugs were excluded.
After written informed consent was obtained, a 3 mm punch biopsy was taken from the area within the lesion which appeared clinically to be the thickest. A 5.0 Vicryl rapide suture was used to close the biopsy site. Histology was performed on each specimen including Breslow thickness.
Six patients were treated in each of the control groups (ALA alone and CP94 alone) (control groups) and 6 patients were treated with each escalating dose of CP94, 3 per centre in parallel.
Two weeks following the biopsy, the patients were allocated into one of the following groups in strict order of recruitment at each centre: Patients were asked to comment on any adverse reactions such as irritation during the time of cream application and an observation of the treated area was made to assess any contact skin reaction such as erythema prior to irradiation.
Six hours following application of the cream, the lesion was illuminated by a filtered narrow-band (630 nm +/-15 nm) red xenon light source (Photo Therapeutics Limited, UK, 100 J/cm 2 , <130 mW/cm 2 ). Six hours is the standard preillumination interval for ALA-PDT for BCC up to 2 mm thick 20 .This activating red light was delivered, in a continuous manner to the entire lesion and to at least a 5 mm margin of adjacent skin.
The treatment regime employed, apart from the incorporation of the CP94, was therefore the same as our standard dermatological ALA-PDT protocol. Pain levels during treatment were assessed by the patient on a 0-10 visual analogue scale. The patients were asked to grade their pain during illumination by drawing a line through a scale where 0 represented no pain and 10 represented intolerable pain. The treatment area was also assessed clinically, post irradiation to check for phototoxic reactions such as erythema. In all cases, at 6 weeks following the single PDT treatment, clinical response rate was assessed and surgical excision of the whole treatment site was undertaken for histology. Previous photographs, skin landmarks and precise measurements were used to ensure exact excision margins. Histolological examination was carried out on each specimen by the one dermatopathologist at each centre, using transverse bread slice histological examination and maximum Breslow thickness of the tumour was measured. The dermatopathologists were blinded in that they received the specimens without knowledge of the treatments received. Blood samples were taken for liver function tests prior to and 1 week following application of the iron chelator, to assess any adverse effect on liver function. Blood results Liver function tests were not altered in any of the patients following treatment.
RESULTS

Immediate clinical observations
Histological results
The clinical and histological response to all 36 treatment sites, 6
weeks following the ALA-PDT treatment is shown in Table 1 . In the CP94 control 
DISCUSSION
This safety study was designed to assess the clinical feasibility and potential advantage of the addition of CP94 to routine dermatological ALA-PDT in this first clinical investigation of this novel pharmacological modification.
The results have shown that the addition of CP94 to ALA-PDT would appear to be safe, with no dose-limiting adverse events noted in any of the 30 patients treated with CP94 during this investigation. The CP94 mixed well with the 20% ALA with no apparent separation and was used immediately following preparation. Further studies to assess stability will be required in the future to increase convenience. There were no increased side effects such as erythema noted before or after illumination with increased concentrations of CP94, over that observed with the ALA only controls. This is in contrast to a study carried out applying different concentrations of ALA via iontophoresis, to normal skin previously treated with DFO, where there was a significant increase in erythema using ALA+ DFO compared with ALA alone 21 .
There was also no apparent increase in pain noted during illumination, when increasing concentrations of CP94 were employed. Pain during irradiation is one of the most frequent side effects that can be observed during dermatological PpIXinduced PDT, so this finding was reassuring. Irradiation-induced pain is thought to be associated with an effective PDT treatment taking place. Previous studies however have shown that pain scores do not correlate with the intensity of PpIX fluorescence either during ALA-PDT of tape stripped normal skin 20 or during ALA-PDT of skin cancer 22 . This suggests that pain associated with ALA-PDT is not simply due to the These findings are in contrast to studies using other iron chelating agents particularly DFO, where the addition of DFO to the higher ALA dose being employed in clinical treatment did not significantly enhance PpIX levels, when examined in matched lesions in the same patient 21 . CP94 however is of lower molecular weight and higher lipophilicity than DFO. It is also neutrally charged in both iron free and iron complexed forms enabling it to move freely in and out of cells by simple diffusion 23 .
CP94 consequently enters the intracellular iron pools more readily and it is this factor which is most likely to account for the increased effect of CP94 over DFO. Studies support the efficacy of CP94 in the enhancement of ALA-PDT of normal colon and bladder tissue in animal models 18, 24 and in normal and malignant cell lines 15, 16 .
Studies using digital imaging fluorescence microscopy have revealed inter-and intratumour fluorescence variability and heterogeneity in BCC treated with ALA for the standard 6 hours application time 26 .A relatively stable level of fluorescence existed from the epidermis to some depth, after which a quantifiable gradient of decreasing PpIX fluorescence intensity versus depth was seen 26 .The ability of CP94 to increase PpIX fluorescence particularly in cells where the concentration of ALA is low may explain the increased effect in deeper nodular tumours 16 . The addition of CP94 would enable the production of clinically useful amounts of PpIX deeper in the tumour cells, where otherwise PpIX production would be at sub-lethal levels.
Further studies are now underway to explore and confirm these observations and to determine the optimal concentration of CP94 to achieve maximum effect. It may be expected that there will be a limit to the addition of the iron chelator to the mixture both physically and also beyond which there would be insufficient ALA present as a substrate, to further increase the levels of PpIX to produce greater enhancement of 16 treatment effect. Studies are also underway to measure the time taken to achieve maximum PpIX concentration with increasing doses of CP94 as it may be possible to allow shorter drug-light intervals if PpIX formation is optimised sooner particularly when treating superficial disease.
The combined use of ALA+CP94 in conjunction with penetration enhancers such as DMSO, tape stripping or iontophoresis, or the use of pressure techniques such as oxygen pressure injection (OPI) 27 may further increase the proportion of nBCC completely responding to PDT treatment.
This study therefore has indicated that this enhanced therapy with CP94 provides a simple and safe pharmacological modification to dermatological ALA-PDT which may increase the proportion of BCC that can be treated by this therapy. This may be a real advance in improving the response rate in these nodular tumours without the need for repeat treatment cycles, although this will require confirmation in a large randomised controlled trial. Table 1 .
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